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Abstract. B cell chronic lymphocytic leukemia (B-CLL) is known to have
substantial clinical heterogeneity. There is no cure, but treatments allow for
disease management. However, the wide range of clinical courses experienced
by B-CLL patients makes prognosis and hence treatment a significant chal-
lenge. In an attempt to study disease progression across different patients via
a unified yet flexible approach, we present a mathematical model of B-CLL
with immune response, that can capture both rapid and slow disease progres-
sion. This model includes four different cell populations in the peripheral blood
of humans: B-CLL cells, NK cells, cytotoxic T cells and helper T cells. We
analyze existing data in the medical literature, determine ranges of values for
parameters of the model, and compare our model outcomes to clinical patient
data. The goal of this work is to provide a tool that may shed light on factors
affecting the course of disease progression in patients. This modeling tool can
serve as a foundation upon which future treatments can be based.
1. Introduction. Chronic lymphocytic leukemia (CLL, also referred to as B-CLL
in the literature) is characterized by the existence of large numbers of white blood
cells (B cells) in the blood, the bone marrow, the spleen and in the lymph nodes.
Until recently, it was believed to be a slowly progressing disease of accumulation
of abnormal B cells that were immunologically challenged, and not a disease of
proliferation of these cells. It is now understood that B-CLL is a heterogeneous
disease in which cells of differing functionality may continue to proliferate, with
dynamics varying from patient to patient. Further details on the biology of the
disease and proposed treatments can be found in several publications [1, 2, 3].
Our goal in this paper is to capture in a mathematical model the underlying
dynamics of this disease by considering the development of B-CLL cells along with
three important components of the cellular immune response to B-CLL: natural
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killer (NK) cells, helper T cells and cytotoxic T cells. The biological literature
reveals [1, 4, 5, 6, 7] that NK cells, helper T cells and cytotoxic T cells may all play
a role in stemming the growth of B-CLL. In fact, potential new immunotherapies
that upregulate either NK or T cell activity are being explored [4, 6, 8]. Therefore a
model that includes NK cell and T cell dynamics may serve as a testbed for future
immunotherapy treatments of B-CLL.
Ordinary Differential Equations (ODE) models of the type in this paper have
been used to study various hematological disorders other than B-CLL [9, 10, 11, 12].
The usefulness of any such model lies in how well it emulates a range of observed
phenomena of a disease. A model for B-CLL assuming competition between the
cancer cells and the immune response has been described by Vitale and colleagues
[13, 14] in which the entire immune response is represented by one combined popu-
lation of T lymphocytes. A model of the immune response to chronic myelogenous
leukemia in post-transplantation dynamics using time delays can be found in [15]
where, again, one immune response is considered. However, the biological immune
response to B-CLL involves several cell types. The model we present explicitly
tracks the innate, helper, and specific immune responses with three separate cell
populations. We examined published data for B-CLL patients to determine the
appropriate functional forms in our ODE model. We compare the model to patient
data in the medical literature, in particular, those provided by Messmer et al. [16].
A significant challenge in mathematical modeling is the identification of meaning-
ful parameter values. An important contribution of this work is the determination
of parameter values that give rise to biologically realistic simulation outcomes. The
parameters for this model are obtained through a careful process of mining and
cross-checking the medical literature for known measurements. A sensitivity analy-
sis reveals the variability of model outcomes with respect to the parameters, and also
suggests the parameters that are most highly correlated with positive or negative
disease progression.
2. Mathematical model. We use a system of four ODEs representing interacting
cell populations of B-CLL and three immune responses in the peripheral blood. We
include the natural killer (NK) cells which are present in the body at all times and
are not specific to B-CLL, cytotoxic T cells (e.g., CD8+T) which respond specifically
to B-CLL, and helper T cells (e.g., CD4+T) which are part of the specific immune
response and which aid in the recruitment, proliferation and activation of cytotoxic
T cells. This ODE model ignores spatial effects: the biological assumption is that
the cell populations are uniformly mixed in the peripheral blood. Concentrations of
B-CLL cells, NK cells, killer T cells and helper T cells (in units of cells per µliter)
are represented by B, N , T and TH respectively. Time is denoted by t (days).
The system of ODEs is given by
dB
dt
= bB + (r − dB)B − dBNBN − dBTBT (1)
dN
dt
= bN − dNN − dNBNB (2)
dT
dt
= bT − dTT − dTBTB + kaTH
BL
s+BL
TH (3)
dTH
dt
= bTH − dTHTH + aTH
BL
s+BL
TH (4)
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A description of the model terms follows.
B-CLL Cells: The dynamics of the B-CLL population are represented by equa-
tion (1). Only B-CLL cells, and not healthy B cells are considered. One of the goals
of this model is to describe and explore the kinetics of the interactions between B-
CLL cells and the immune response. It has been noted that normal B cells do
not play a large role in the immune response to B-CLL [17], and that, in a B-CLL
patient, B cell levels are orders of magnitude larger than B cell levels in a healthy
person. The large number of B cells and the lack of evidence for healthy B cell
activity in a B-CLL patient, leads to the decision only to track B-CLL cells in this
model. In other words, if a healthy B cell population were included in the model,
it would decouple from the other equations. While, in a healthy person, homeo-
static mechanisms certainly play a role in keeping the B-CLL phenotype population
very small, we are concerned here with situations in which the B-CLL cells have
escaped these control mechanisms [18]. In equation (1), the term bB represents a
constant source of B-CLL cells from another compartment, such as bone marrow.
The term (r − dB)B represents the density dependent change of the leukemic pop-
ulation, that is, the net increase or decrease due to division and death of leukemic
cells. Leukemic cell losses due to interactions with NK cells and effector T cells are
represented by the terms dBNBN and dBTBT respectively. These terms assume
mass action between B-CLL cells and NK and T cells, an assumption that is jus-
tified by our previous assumption that the cell populations are well mixed in the
blood, so that direct interactions between cells occur at a rate proportional to their
concentrations.
Natural Killer Cells (NK): We represent the NK dynamics in equation (2).
There is some evidence that although natural NK activity may be weak in B-CLL
patients, there is a treatment possibility involving expanding NK cells from the
peripheral blood of B-CLL patients, and further there is evidence that these cells
have cytotoxic capacity [4, 6]. In general, NK cells recognize “non-self” cells, and
eliminate them.
In this model, we assume NK cells are being produced at a constant rate, inde-
pendent of the presence of B-CLL. We represent a constant source rate of NK cells
with the term bN . The death rate, dNN, is proportional to the existing NK pop-
ulation. NK cells may become deactivated once they have interacted with B-CLL
cells. Deactivation through contact with the B-CLL cells is represented through
the mass action term dNBNB. As above, the mass action term is justified by our
previous assumption of well-mixed cell populations.
Cytotoxic T Cell (CD8+T): Equation (3) represents killer T cell dynamics in
our model. We include killer T cells in this model since there is evidence that T
cells have a therapeutic effect on B-CLL. This effect may additionally be enhanced
through the use of tumor vaccine [8, 17]. T cell population growth is represented
by bT , and natural death by dTT .
There is evidence that the cytolytic activity of specific T cells is mediated through
the perforin-granzyme pathway [17]. Therefore, after a number of encounters, a T
cell can no longer induce lysis due to lack of perforin. Furthermore, it has been noted
experimentally that the leukemic clone produces large amounts of various immune
suppressive factors [17]. In order to reflect this suppression of T-cell activity and
gradual deactivation in the model, we include a deactivation term for the killer T
cells, just as we do for the NK cells. Deactivation by encounters with B-CLL
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cells has a mass-action form, dTBTB., similar to the analogous term in the NK
equation.
Cytotoxic (or killer) T cells are part of the specific immune response, and must
be primed to recognize and attack a particular target cell. We do not include in our
model the entire cascade of events that leads to the priming and activation of the
killer T cells, but we do include a term describing the recruitment and activation
of CD8+ killer T cells by helper T and B cells. The T cell recruitment term,
kaT
BL
s+BL
TH , is a fraction, k, of the newly activated CD4
+ helper T cells. This
saturation limited term contributes to the CD8+ killer T cell population in a manner
proportional to the existing CD4+ helper T population. The ability of B-CLL cells
to stimulate the recruitment and activation of T cells through helper T cells will
in general increase as the concentration of B-CLL cells in the system increases.
However, T cell recruitment and activation is limited by an upper threshold. This
recruitment action is assumed to occur in the lymph system where there may be
disproportionately more B-CLL cells compared to CD4+ helper T cells. Saturation-
limited dynamics are commonly used when modeling immune cell recruitment, as
in Moore and Li [11] and de Pillis et al. [19].
Helper T Cells (CD4+T): Equation (4) represents helper T cell activity.
Helper T cells are an essential component in the priming and stimulation of the
CD8+ killer T cells. However, the helper T cells do not actually lyse the B-CLL
cells in the system [20]. For this reason, we do not include a deactivation term by
B cells in the helper T cell equation. We include growth, death, and stimulation
and recruitment. We assume constant growth and exponential death, given by the
terms bTH and dTHTH , respectively. Stimulation and recruitment are represented
by the saturation-limited term aT (
BL
s+BL
)TH .
3. Parameters and data fitting. We used several sources in the literature to de-
termine and cross-check parameter value ranges for our model. Although parameter
values within a patient may not be static, for a given simulation we approximate
the parameters by a fixed value, representing an average value over time for that
particular parameter. Furthermore, parameter values will vary from patient to pa-
tient.
Table 1 provides values for all the parameters in the model equations (1) - (4).
Details about the sources and methods of estimation of these parameters have been
included in comments 1 - 16 of Appendix B. Table 2 provides ranges for biological
values of the initial cell concentrations. Details about the sources and methods of
estimation of these parameters have been included in comments 1 - 3 of Appendix
C .
The study of Messmer et al. [16] provides in vivo B-CLL proliferation and turn-
over data measured in a group of nineteen patients. We used these measurements
to assign value ranges to our model parameters r and dB . The Messmer study addi-
tionally provides time series B-CLL data within each patient. The data Messmer et
al. present are the number of B-CLL cells within each patient, over approximately a
200 to 250 day period, that are marked with deuterated water (2H2O - “heavy wa-
ter”). This cell count represents a fraction of the entire B-CLL population within
the patient. Messmer et al. also propose two simple mathematical models that
track only cell birth and death dynamics. They compare their model simulations
describing the dynamics of the marked B-CLL population to the measured patient
data. For certain patients, good model fits to the data were not found. This is
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not surprising, since the model only tracks birth and death of cells, and does not
account for any other cell dynamics, such as immune system interference. It is com-
mendable that, using such a simple model, good model fits were found for many of
the patients.
Our mathematical model incorporates immune system dynamics, in addition to
B-CLL growth and death terms. For certain phenomena, such as tumor dormancy,
immune system dynamics have been found to provide one explanation for the pro-
gression of cancers that might not otherwise be explained by birth and death cycles,
or treatment interventions [21, 19]. We do not claim that the addition of the im-
mune system is the only way to capture more complicated dynamics, but we do
claim that immune system interactions provide one possible explanation for some
observed patterns. Using the data from Messmer et al., we found that the presence
of the immune system in our model does allow us to capture B-CLL progression
patterns in certain patients that otherwise cannot be captured by a simpler model.
However, our model equations represent dynamics of the entire B-CLL population,
and not just a subset marked with heavy water. In order to calibrate our model out-
comes to the patient data provided in this paper, we had to introduce an equation
representing heavy water uptake.
Allowing H(t) to represent the fraction of heavy-water marked B-CLL cells, the
change over time of the labeled cells population can be described by
H ′(t) = (fraction of new cells labeled) ∗ (number new cells)− (cells dying off)
Translating this into mathematical terms, the following equation models the time
dynamics of the fraction of heavy water marked B-CLL cells:
dH
dt
= h(t)(bB + (r − dB)B)− dBH(t) (5)
Note that H is a function of the entire B-CLL population B, but equations (1)
-(4) do not depend on H. The H(t) population dynamics are different from those
of the larger B-CLL population. Messmer et al. [16] administered heavy water to
the nineteen patients for 84 days, and then measured marked B-CLL cells by using
mass spectroscopy to count the fractions of leukemic cells that incorporated heavy
water in their DNA before and after stopping heavy water intake. Once the heavy
water infusion is stopped, no new H(t) cells are created, and this cell population
begins to die off. Hence, while the birth and death parameters of the marked B-CLL
population are the same as those for the larger B-CLL population, the H dynamics
depend on the degree of cell labeling in newborn cells.
The function h(t) in equation (5) represents the percent of heavy water loading
in the cells, and is given by the following equations:
h(t) =

.03
(
1− e−fwt) 0 ≤ t ≤ 5
.01 + (h5 − .01)e(fw(5−t)) 5 < t ≤ 84
h84e
(fw(84−t)) 84 < t,
where
h5 = .03(1− e−5fw), and h84 = .01 + (h5 − .01)e−79fw .
The parameter, fw is the fractional daily water exchange, and is patient specific.
This parameter can be estimated, as described in [16], from the patient’s body
weight and the prescribed heavy water protocol. Estimates for the data sets used
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in this paper are given in Table 3. The derivation of the equation for h(t) can be
found in [16] and, for completeness, in Appendix D.
We carried out a least squares fit of equation (5), used in conjunction with our
model equations (1) -(4), to patient data in Messmer et al. [16]. These results are
displayed for 6 patients in Figures 1 and 2.
The data for these six patients, represent a variety of disease progression patterns.
These data sets were chosen to test our model’s ability to reflect a range of disease
dynamics. We present fits to patients 109, 331, 332, 355, 360 and 418 from the
Messmer study. Of those data sets, the Messmer birth-death models were unable
to obtain satisfactory fits to data from patients 109 and 418.
As can be seen in the lower panels of figures 1 and 2, we are able to obtain
reasonable fits to all six sets of patient data with our model equations, including
the data from patients 109 and 418. Other patient data sets, such as that for patient
360, were considered by Messmer et al. to have been reasonably well captured by
their models. However, upon comparison between figure 2 in this paper, and figure 3
of Messmer et al., it can be seen that even in the case of patient 360, the addition of
the immune component in our model allows for a closer prediction to the dynamics
of the labeled B-CLL cells population. In particular, in patients 360 and 418, our
heavy water equation fitted to the data predicts a sharp increase and subsequent
decrease in the fraction of labeled cells, a dynamic that reflects the patient data
well, but that is difficult to capture in the absence of immune system interactions.
The patient data provided in Messmer et al. [16] also give a means to obtaining
additional model parameters that may not be available in the literature. The model
parameters that can be obtained through fitting to the Messmer patient data are
presented Table 3.
4. Results.
4.1. Sensitivity and uncertainty analyses. In order to determine the effect
of our estimates on model outcomes, a sensitivity analysis was performed on all
parameters of the model. Ten thousand values were drawn for each parameter
from a uniform distribution that was supported on the intervals specified in Table
1. A Latin Hypercube sampling method was used to randomly select vectors of
parameter-values to be used for each run. Details of the Latin Hypercube Sampling
procedure can be found in the paper by Blower et al. [22]. The distribution of all
cell counts after 1 month, 2 months and 8 months of simulation are shown in Figure
3.
We note that, after eight months of simulation, all of the four cell populations are
zero for most of the parameter values. The cytotoxic and helper T cells are either
zero or at a very high level, while the B cells and NK cells cover a wider range of
values. This observation leads us to conclude that, for the parameter ranges used,
the disease has died out after 8 months in 82.4% of the cases (this is the number of
simulations that result in a B-CLL count close to zero after 8 months). Furthermore,
cytotoxic T cell levels remain high after 8 months only 5% of the time. From the
distributions presented here, we are unable to say whether the high levels of T-cells
persist when the B-CLL levels are high, but a further analysis (data not shown)
reveals that B-CLL levels after 8 months are generally low in the 5% of the cases
when both T cell and TH cell levels are high. Thus, there is a heterogeneity in the
population whose disease is in remission: some have significant T cell activity while
others do not.
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Figure 1. Model simulations, fit to Patient 109, 331 and 332
data from [16].
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Figure 3. Distribution of the four cell types for the 10,000 pa-
rameter choices selected using the Latin Hypercube Sampling tech-
nique. In each of the sub-panels, the x-axis shows the number of
cells and the y-axis shows the fraction of the 10,000 runs that re-
sulted in the given cell number. The variability in cell number that
is observed in the first month of simulation has largely disappeared
after 8 months.
Partially ranked correlation coefficients (PRCC) and their associated p-values
were calculated from these 10,000 simulations where ranked parameter values were
correlated with the 8-month and 2-month levels of B-CLL and the three immune
cell types: NK, T and TH cells. Only those parameters that were monotonically
related to the outcomes were considered in the analysis. In Figure 4 we show those
parameters that have an obvious correlation with the outcome, and whose PRCCs
are significant at the .001 level. We show here the analyses at two months and
8 months because they show some variety in correlation to outcome, while clearly
pointing out some significant parameters. We performed the same analysis at one
month, but fewer parameters were found to be significantly related to outcomes.
The PRCC values shown in Figure 4 are displayed in Table 4.
The sensitivity analysis can help to identify model parameters that could be
particularly important to the progression of the disease. For example, the rate of
influx of new B-CLL cells from the solid organs or mutations, represented by bB in
the model, has a positive correlation coefficient, both with the initial growth of the
B-CLL cell population as well as with the final B-CLL counts. On the other hand,
aTH a coefficient corresponding to the recruitment of new T-cells, is negatively cor-
related with the final B-CLL outcomes both in the initial and later stages of the
disease indicating immune cell recruitment and activation are important consider-
ations in reducing disease burden. Parameters negatively correlated with B-CLL
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Figure 4. The upper panel shows the parameter correlation values
with cell population levels at 8 months. The lower panel shows PRCC
values for cell population levels at 2 months. There are more significant
parameters in the early days of the model dynamics as compared to later
days.
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outcomes, which show a reduced correlation as disease progresses, like dBT , indicate
a reduced effect of the immune system over time. Since dBT represents the ability
of T cells to kill B-CLL cells, cell lysis assays may be good prognostic indicators.
The PRCC results shown in Figure 4 indicate that the parameter aTH has a
strong positive correlation with NK, T and TH levels, and as noted earlier, a
strong negative correlation with diseased B cell levels. These correlations persist
through the first 8 months of simulation. The correlation is not surprising, since
aTH represents the strength of the T cell recruitment. Furthermore, the parameter
aTH varies from patient to patient, as can be seen in Table 3.
4.2. Bifurcation analysis. We can gain a great deal of qualitative information
about disease progression by studying the long term behavior of the system of ordi-
nary differential equations that describes the model. For example, if the system has
stable equilibria, or steady states, then the system may move towards one of these
steady states if it is initially in the basin of attraction of a stable equilibrium. The
first step in such a stability analysis involves finding the equilibria of the system,
typically using numerical methods. Local stability can then be determined by lin-
earizing the system near the equilibria, and then by determining the stability of the
linearized system. Often, the location and stability of these equilibria depends on
the values of the parameters: determining this dependence can give further insight
into the role of a parameter on the disease outcome. A bifurcation analysis involves
determining the location and stability of equilibria for a range of parameter val-
ues, and then identifying parameter values at which a qualitative change in system
behavior occurs.
We have automated this process using Matlab. For each parameter value, we
use a numerical root-finding routine to find equilibria, by finding the roots of the
right-hand side of the system of ODEs. We then numerically find the eigenvalues of
the Jacobian of the system, evaluated at biologically relevant equilibria (i.e. those
that are non-negative) in order to determine the stability of the equilibria. We can
plot the results as a function of the parameter value to locate any bifurcations, such
as parameter values at which an equilibria changes stability, or at which equilibria
appear or disappear.
Since the parameter measuring the strength of the adaptive immune response,
was found to have the most effect on both the short and long term evolution of the
system, we performed a bifurcation analysis with respect to the parameter aTH .
Since this is a fairly standard procedure, we omit the details, and just give the
results. The analysis, depicted in the top panel of Figure 5 shows that a saddle
node bifurcation occurs at aTH ≈ 8.5 × 10−6. The qualitative trend shown in the
Figure make sense: as aTH decreases, the stable equilibrium value of the B-CLL
cell population rises, while the equilibrium values of the NK cell and T cell popu-
lations fall steadily (not shown). For sufficiently small values of aTH , for example
aTH = 8.1× 10−6, all equilibrium values vanish via a saddle node bifurcation, and
B cell populations can grow without bound. For aTH values greater than the bifur-
cation point at approximately 8.186 × 10−6, the behavior of the B cell population
is determined by the initial conditions. The trajectories in the lower two panels of
Figure 5 illustrate these dynamics.
We note that other parameters shown to be significant in the sensitivity analysis,
such as dTH and dBT give rise to similar bifurcation scenarios. While we do not re-
produce the diagrams here since they are qualitatively similar to the one shown, any
therapy that manipulates these parameters would motivate a careful study, using
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Figure 5. Graphics showing the effect of varying the T cell
recruitment parameter, aTH . Top: Two equilibria co-exist for
aTH > 8.186 × 10−6, with no equilibria at lower values. Arrows
along the line aTH = 8.5× 10−6 mark initial values (B0) for which
simulations are shown in the center panel. The upper branch in-
dicates unstable equilibria, while the lower branch indicates sta-
ble equilibria. Center: Solutions with B0 = 80c/µL, and B0 =
140c/µL converge to the stable equilibrium while B0 = 180c/µL
yields an increasing solution that moves away from the unstable
equilibrium at BE1 = 172.2. Note that the trajectory starting at
B0 = 80c/µL first rises above the stable equilibrium at BE2 = 97.4
, and then decreases towards it. Bottom: With B0 = 140 and
aTH < 8.186 × 10−6, B cell concentrations grow without bound,
while increasing aTH above 8.186× 10−6 results in a stable B cell
concentration. Other parameters are given in Appendix E.
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the same techniques described above, to determine critical values of the parameters
and approximate basins of attraction. Indeed, a careful study of all parameters in
the model might uncover other types of bifurcations and other limiting behavior
such as limit cycles or other types of attractors. We leave this for future work.
In this model it is clear that the NK and T components of the immune system
keep B-CLL growth under control. Figure 6 shows a simulation in which the disease
level approaches a low stable equilibrium. That is, the B-CLL population rises to
approximately 100 cells per µliter and remains there for some time (till day 2000
in our simulations). This could correspond to a patient with undetected low level
illness. For this hypothetical patient, we simulate a compromised immune system
by setting dBN = 0 and dBT = 0 on day 2000 in our model. As a result, the B-CLL
cell population begins to grow rapidly, as shown in the right half of Figure 6.
Our good qualitative fits to several patients’ data sets demonstrates that this
model can be implemented across a range of disease behavior and in patient specific
settings.
5. Conclusion and future directions. We have created a model for B-CLL dis-
ease dynamics that is better able to reflect clinical data than are other existing
models as of this writing. Since the NK and T immune cell populations are un-
derstood to play an important role in B-CLL progression, we believe the model
improvements stem from the incorporation of these cell populations in the model.
The addition of the different immune populations makes it possible to capture a
wide range of disease progression dynamics. For example, the B-CLL populations
in the six patients we have presented show qualitatively different time dynamics:
The increase in B-CLL over the first 84 days of heavy water administration can
follow either a convex or a concave increasing curve, and B-CLL decline after day
84 can be steep, moderate, or almost level. All of these qualitatively different forms
are captured by our model.
The sensitivity analysis we performed revealed which parameter values were more
strongly correlated to disease progression than others. For some of these parameters,
such as those representing tumor birth and death rates, assays exist that can give
patient-specific values for these parameters, potentially improving patient prognosis.
One parameter value, the immune cell recruitment rate, was found to be significant,
but it is not a value that is easily measured in vivo. This parameter may be a good
target for new assay development.
Bifurcation analyses similar to that shown in Section 4.2 can be performed for
other significant parameters in the model. This can help identify critical values of
parameters that could potentially be measured in the clinic. Treatments that drive
parameter values into regions where a relatively small B-cell level is stable would
be indicated in order to slow disease progression. We remark that the values of
aTH fitted to the 6 data sets shown in Table 3 all fall well above the saddle-node
bifurcation point. It is worth noting that this bifurcation point can shift when
other model parameters are changed. With an eye towards personalized medicine,
we might envision these diagrams tailored to parameters measured in the clinic, and
used to design the most efficient interventions.
We have shown that the immune system plays an important role in the pro-
gression of B-CLL observed in the clinic. Useful future model extensions would
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Figure 6. The bottom panel shows the final 250 days of the simulation
shown in the top panel. B cells grow quickly when the immune system is
no longer effective. Parameters are from Patient 331 in Table 3. Other
parameters as in Table 1.
incorporate B-CLL treatments, ideally including both chemotherapy and immune-
modulating treatments. The compartmentalized form of the model we have pre-
sented, which separates out NK, T and helper-T cell dynamics, provides a useful
starting point to modeling treatments that target these specific populations.
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Appendix A. Tables.
Table 1: Model Parameter Values
Numbers (Bn) refer to Appendix B, item n
Name Description Units Reference Value
bB B-CLL
source rate
(cells/µL)(day)−1 Fitted, (B1) [9, 2370]
r B-CLL repro-
duction rate
day−1 Messmer et
al., [16] (B2)
[0.11%, 1.76%]
bTH TH source
rate
(cells/µL)(day)−1 Hellerstein et
al. [23] p.84,
(B3)
[3.9, 16.9]
bN NK source
rate
(cells/µL)(day)−1 Calculations,
(B4)
[1.59, 7.632]
bT Source rate
of activated
cytotoxic T
cells, natu-
rally and due
to therapy
(cells/µL) (day)−1 Estimated,
(B5)
[0, 13.5]
dB B-CLL natu-
ral death rate
day−1 Messmer et
al. [16]
0.0076
dN NK natural
death rate
day−1 Jamieson et
al., [24] De
Boer et al.,
[25] (B7)
0.0159
dBN B-CLL death
by NK cells
(cells/µL)−1(day)−1 Zimmermann
et al., [5]
(B8)
[9.78×10−7, 1.19×
10−3]
dBT B-CLL death
by T cells
(cells/µL)−1(day)−1 Ad hoc value,
(B9)
[3.40×10−5, 1.36×
10−1]
dNB NK deactiva-
tion due to
B-CLL inter-
action
(cells/µL)−1(day)−1 Zimmermann
et al., [5]
(B10)
0.0001
dT T natural
death rate
day−1 Hellerstein
et al., [23]
Abbas et al.,
[26] (B11)
[0, 0.0675]
dTB Inactivation
of cytotoxic
T-cells by
B-CLL
day−1 Estimated,
(B12)
0.0010
Continued on next page
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Table 1 – continued from previous page
Name Description Units Reference Range
dTH TH natural
death rate
day−1 Hellerstein et
al., [23] (B13)
[1.35×10−3, 3.38×
10−2]
s Half-
saturation
level in the
recruitment
term
cells/µL Estimated,
(B14)
10000
k Scaling
factor < 1
unit-less Estimated,
(B15)
0.6
aTH TH activated
by B-CLL
day−1 Estimated,
(B16)
[1.42× 10−3, 7.5×
10−3]
L Power of
B in the T
and TH cell
recruitment
terms
unit-less Estimated,
(B17)
2
Table 2: Possible ranges of Initial Conditions: Sick versus
Healthy. Total Cell Counts per µL
Numbers (Cn) refer to Appendix C, item n.
Cells per µL Healthy Sick Reference
B0 0.3 × 103 up to 3.0× 105 Healthy: Janeway et
al. [20] and Abbas et
al., [26] Sick: Shimoni
et al.[27] (C1)
N0 0.1× 103 − 0.48× 103 1.84×102−6.25×102 Healthy: Janeway et
al., [20] Abbas et al.
[26] Sick: Jiang et al.
[28]
T0 0.3 × 103 − 0.9 × 103 2.4 × 103 − 7.5× 104 T -effector, Abbas et
al. [26] Sick: Guven
et al., [6] Kimby et
al., [29] (C2)
TH0 0.5 × 103 − 1.6 × 103 1.74× 103 − 1.8× 105 Healthy: Abbas et al.
[26] Sick:Guven et al.,
[6] Kimby et al., [29]
(C3)
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Table 3: Values obtained by fitting to values of heavy water
labeled data in Messmer et al. [16]. * In the fitting, we used
rdB = −(r − dB) in place of r as this rate is mathematically
more meaningful as the net reproduction rate of BCLL cells.
We show the data for Patients 109, 331, 332, 355, 360 and 418.
Par Pt 109 Pt 331 Pt 332 Pt 355 Pt 360 Pt 418
aTH .00142 .000421 .00602 .0075 .00377 .00595
bB 14.9 9.81 145 176 976 2370
dB 7980 .00281 .000171 .000143 .00919 .486
rdB∗ .00191 .00182 .0422 57.4 69 128
dBN .000881 .00119 .00023 .00033 .000398 9.78 · 10−7
dBT .000658 .000546 .000669 .000034 .0542 .136
dT .0354 .0924 .00512 .0075 .0075 .000101
dTB .0175 .0201 .000874 .000874 .00099 .00099
k .477 .499 .454 .454 .457 .457
bT 1.67 5.48 142 122 1.32 2.16
B0 34 41.6 240 282 61.7 14.9
N0 504 253 35.3 37.2 352 345
T0 2.0 2.0 84.9 84.9 2.0 2.0
TH0 1 1 1427 1427 1 1
fw 6.66 6 6 5.51 5.51 6.91
Table 4: Partially ranked correlation coefficients for significant
parameters (p < .001). Only 6 parameters are significantly cor-
related with the cell populations at 8 months, as compared to
10 parameters with the cell levels at 2 months.
Parameter Partially Ranked Correlation Coefficient
B-CLL cells NK cells T cells Helper T Cells
8mos 2mos 8mos 2mos 8mos 2mos 8mos 2mos
bB .2725 .3819 -.1746 -.2380 .3434 .1016 .3847 .1067
r .1007 .2316 -.1007 -.1424 -.0611 -.0826 .0419 .0357
dBT -.0360 -.4846 .1121 .4805 -.3546 .1371 -.5002 -.4865
dTB .1428 .5070 -.1722 -.5219 -.1903 -.5433 .5335 .5830
dTH .5021 .1772 -.2868 -.1324 -0.2703 -.1841 -.3683 -.3323
k - -.1047 - .1076 - .1181 - -.1136
aTH -.7881 -.7293 .7422 .7085 .7507 .7906 .4880 .6626
bT - .1032 . - -.0847 - -.0503 .0520
NO - -.1006 - .1143 - .0923 - -.0961
TO - -.3472 - .3480 - .3937 - .4301
Appendix B. Comments for Table 1.
1. bB : Constant source of new B-CLL cells. This term is a small number (com-
pared to the B-CLL cell population) representing the fraction of antigenically
experienced immunologically competent B lymphocytes that become diseased.
There are no estimates available for this term and may have a range of values.
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The patient data fitting has produced values as large as 2370 cells/µ-liter per
day.
2. r: From Messmer et al. [16][Table 1, p.756]. Min: 0.11% Max: 1.76% Mean:
0.4636%.
3. bTH : From Hellerstein et al. [23][p.84] we have bTH = 10.4±6.5 cells per µliter
per day.
4. bN : To get the NK birth rate, we see that our model implies that the steady
state number of NK cells is given by the ratio bN/dN . According to p.17 of
Abbas et al., [26] the number of lymphocytes per µliter in the blood ranges
from 1000 to 4800 with a mean of 2500. From p.19 of Abbas et al. [26] we see
that NK cells are about 10% of all lymphocytes in the blood. Therefore the
numbers of NK cells per µliter are 100 to 480 with a mean of 250. That is,
bN/dN has a mean of 250 and lies in the range [100, 480]. Hence we calculate
the range of values bN = dN×[100, 480] with a mean value of dN×250 =3.975.
We use the value of dN obtained in comment 5. We round to 3 significant
digits so bN = 3.98.
5. bT : From Hellerstein et al. [23][p.84] we have the birth rate of cytotoxic T
cells given as 5.6 ± 7.6 cells per µliter per day which gives a range for bT of
[−2.2, 13.5] cells per µliter per day. We restrict bT to be positive. Since bT is
a source of (activated) cytotoxic T cells, it is also chosen so that in a healthy
steady state, CD4+/CD8+ = 2. The normal range of CD4/CD8 ratio, is
approximately 1 to 4 [20]. This ratio is also used as a prognostic indicator of
a patients well-being [30, 31]. We use bT =
1
2
dT bTH
dTH
in our programs so as to
ensure that the CD4+/CD8+ ratios are in a biologically relevant range. In
the model we have used bT to represent a natural source as well as a therapy
source. bT can be increased when therapy is applied. Values obtained after
fitting this parameter to patient data vary from 1.32 to 142 cells per µliter
per day, different from the range suggested by Hellerstein et al.
6. dB : Messmer et al. [16] calculated death rates for 19 patients as the difference
of birth and growth rates they obtained. Since they obtain these values by
means of fitting their single and double compartment model to heavy water
data they report a few negative values for death rate. Messmer points out
that patients with cell birth rates greater than 0.35% were much more likely
to develop progressive disease. Taking the average cell death rate from this
subgroup of patients (those with cell birth rates greater than 0.35%), yields
an average cell death rate for this group of 0.76%. This is the value we use
when carrying out the model sensitivity analysis. For patient simulations, the
value of dB is fit to the individual patient profile. Individual values of dB
obtained from fits range from 0.014% up to 48.6%.
7. dN : NK cell natural death rate (per day). Since estimates for this parameter
are not available for humans, we extrapolate existing data for animals as
described here. From Jamieson et al. [24] (mouse data) and De Boer et al.
[25] (monkey data), and the allometric scaling work by West et al. [32], we
find a scaling factor = Rate/(Massx) that has the same value across species.
We find that x = log(R1/R2)log(M1/M2) (where R1=rate of species 1, e.g., NK cell
death rate in species 1, M1=mass of species 1, etc). In particular we use
R1 = (0.0294+0.0412)/2 =0.0353, the average value for mouse NK cell death
rate. In Jamieson et al. [24] the half-life of the mouse NK cell is 17 days.
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Hence the lifespan of NK cells is 34 days and the death rate = 134 = 0.0294.
From Kuznetsov et al., [21] R1 = 0.0412. From De Boer et al. [25] R2 = 0.02
for monkey NK cell death rate. We assume the range of mouse weight is 0.018
Kg to 0.034 Kg, giving M1 = (.018 + .034)/2 = 0.026. We use M2 = (5.34 +
7.7)/2=6.52, since we assume the range of monkey weight is 5.34 Kg to 7.7 Kg.
We get x = −0.102845. Applying the same logic to get the death rate of NK
cells in a human, we get a scaling factor of R2/(M2)x = 0.024253. Assume
an average human weighs 60 Kg, i.e., M3 = 60. Then NK death rate for a
human is given by R3 = scaling factor ×(M3)x = (R2/(M2)x)× (M3)x = dN
= 0.015918. Rounding to 3 significant digits gives dN = 0.0159.
8. dBN : This B-CLL per-day kill rate by NK cells has a value close to zero.
According to Figure 7A of Zimmermann et al., [5] for patients with Acute
Lymphocytic Leukemia (ALL, not B-CLL), NK cells have a low interaction
rate with ALL cells. No data values for dBN specific to B-CLL are available
at the time of this writing. As a result of fitting parameters for six patients
described in [16] , we obtained dBN values ranging from 9.78× 10−7 to 1.19×
10−3.
9. dBT : No direct measurements of B-CLL kill by T cells were available at the
time of this writing. Ad hoc value. We choose a value in the same order of
magnitude as other killing rates.
10. dNB : According to Figure 7A of Zimmermann et al., [5] for ALL (Acute
Lymphocytic Leukemia) patients, there is only low-level interaction between
cancer cells and NK cells. We assume this to be true of B-CLL as well and
fix the value to be 0.0001 cells/µ liter per day.
11. dT : Data from Hellerstein et al. [23] and confirmed in McClean and Michie.
[33] For healthy individuals, Hellerstein et al. [23][p.84] give source rate (bT ) of
cytotoxic T cells to be 5.9±7.6 cells per µ−liter per day, which gives a range of
[−2.2, 13.5] cells per µliter per day. Assuming that dT/dt = bT−dTT, we know
dT = (bT /T ) in steady state. We use T cell values from Abbas et al. [26] to be
in the range [200, 1200], and allowing for only positive values for dT we get the
range of possible values to be [0, 0.0675] (per day) for dT . Note 13.5/200 =
0.0675 is the high end value of bT . We use the value dT = 0.005 which lies in
our range. Hellerstein et al. [23] also provide “Fractional Replacement Rate”
numbers for healthy humans, which are equivalent to “death rates” in our
model. The ranges Hellerstein et al. [23] give for CD8+T cells are .009± .013
(fraction per day). Using only positive values, this gives a range of [0, 0.022]
(fraction per day). Note: This range for CD8+T cell death rates lies within
our calculated ranges above. The ranges in Hellerstein et al. [23] are smaller,
since they use total CD8+T cell counts based on the patients tested, while we
use “normal counts” given in Abbas et al., [26] which are broader.
12. dTB : No direct measurements of T cell kill by B-CLL cells were available at
the time of this writing. As a result of fitting this parameter to patient data
we obtained values varying from 9.9× 10−4 to 2.07× 10−2.
13. dTH : Hellerstein et al. [23] data with steady state growth assumption produces
a range of values from 0.0013542 to 0.0338 per day. If from our model we
assume that dTH/dt = bTH − dTHTH then in steady state, we know that dTH
=
bTH
TH
. According to Abbas et al. [26][p.17], the mean number of lymphocytes
per µliter in the blood is 2500 and ranges from 1000 to 4800. From Abbas et
al. [26][p.19] we see TH cells form about 50%− 60% of all lymphocytes in the
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blood. So the number of TH cells per µliter is in the range [500, 2880], i.e., the
equilibrium value of TH in the absence of B-CLL,
bTH
dTH
, is in this range. Thus
bTH
TH
= (10.4±6.5)500 to
(10.4±6.5)
2880 which gives .0013542 to 0.0338 per day. We use
the value dTH = 0.010 which lies in the calculated range. Hellerstein et al. [23]
also have “Fractional Replacement Rate” numbers for healthy humans, which
are equivalent to “death rates” in our model. The ranges given in Hellerstein
et al. [23] for CD4+ are 0.008±0.005 (fraction per day) which implies a range
of [0.003, 0.013] (fraction per day). Note: This range for CD4+T cell death
rates lies within our calculated ranges above. The ranges given in Hellerstein
et al. [23] are smaller, since they use total CD4+T cell counts based on the
patients tested, while we use “normal counts” given in Abbas et al., [26] which
are broader.
14. s: Constant value in the saturation limited term for T cell and TH -cell re-
cruitment by B-CLL. s represents the number of B-CLL cells per µliter that
give rise to half of the maximum T cell recruitment potential. The ad hoc
value assigned to s is 10000. The dynamics do not change too much for a
wide range of values that we tried.
15. k: This scaling factor represents the relative rate of T cell to TH cell recruit-
ment by B-CLL cells. We assume that B-CLL cell recruitment of the helper
TH cells is stronger than that of cytotoxic T cells. Therefore k < 1. We use
an ad hoc value of k = 0.6.
16. aTH : This term, representing the strength of TH cell recruitment by B-CLL
cells, is an estimate that was arrived at by running several ODE simulations
and using values that gave a reasonable range of outcomes. Thus we assigned
a baseline value to aTH of 0.0003. The PRCC analysis showed aTH to be a
significant parameter and therefore we found the best estimates for aTH using
the data for the six patients described in Table 3. These were found to be
between 1.42× 10−3 and 7.5× 10−3, giving the range reported in Table 1.
17. L: An exponent L greater than 1 in the recruitment term for T cells and
TH cells implies that recruitment becomes more efficient as B-CLL densities
increase from very low to moderate values. In predator-prey models, this
term has a form similar to a Hill function used to represent type III func-
tional responses. If the exponent L were equal to 1, the function is then of
the Michaelis-Menten form, used to represent type II functional responses.
The Michaelis-Menten response curve allows for immediate response to low
density stimulation and is saturation limited for high-density stimulation. In
contrast, the Hill response curve gives a slower initial response to lower den-
sity stimulation (e.g. L = 2), and is also saturation limited to high density
stimulation. We choose L = 2 because we want slow initial response to low
density stimulation.
Appendix C. Comments for Table 2.
1. Healthy total B cell count is about 0.3× 103 cells/µ-liter. [26, 20] Shimoni et
al. [27] indicates that for sick patients, the total B-CLL cell count can go as
high as nearly 300× 103 cells per µliter.
2. If total lymphocyte count in sick B-CLL patients is 12×103 to 300×103 cells
per µliter, [6, 27, 29] and if CD8+ T cells are 20 − 25% of all lymphocytes,
[26] then the range is 2.4× 103 − 7.5× 104 cells per µliter. Our T0 = bT /dT ,
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(steady state values) and this puts us into acceptable biological range of T
cells. There is some evidence that T cell counts in B-CLL patients may be
higher in healthy patients, and in fact some of the Messmer et al. [16] patients
have highly variable B-CLL counts as a fraction of WBCs.
3. If total lymphocyte count in sick B-CLL patients is 12×103 to 300×103 cells
per µliter, [6, 27, 29] and if the CD4+ T cell count is 50-60% of lymphocytes,
[26] then the CD4+ range is 6× 103 − 180× 103 cells per µliter.
Appendix D. Derivation of h(t). The function h(t), representing the percent of
heavy water loading in the B-CLL cells, is derived as follows. (This derivation is
also in [16].)
The change in h over time can be described by the ordinary differential equation
(ODE)
h′(t) = fw(hin − h),
where fw is the fraction of daily water exchange: fw =
Daily water turnover rate
Total water in body
.
In the protocol used to gather the data in Messmer et al. [16], hin = 3 % from
day 0 to day 5, hin = 1 % from day 5 to day 84, and hin = 0 percent from day 84
on.
We can solve the ODE describing h(t) through separation of variables. Assuming
the initial value of h is 0, that is, h(0) = 0, we have
1
hin − hh
′ = fw ⇒ h(t) = hin
(
1− e−fwt) .
This yields:
h(t) = .03
(
1− e−fwt) , 0 ≤ t ≤ 5,
and at day 5,
h(5) = .03(1− e−5fw) = h5.
To find h for the next time range, we then solve for h(t) for 5 ≤ t ≤ 84, and set
hin = .01. We use the initial condition h5 from above. This gives:
h(t) = .01 + (h5 − .01)efw(5−t), 5 ≤ t ≤ 84.
At day 84, we then see that h(84) = h84 = .01 + (h5 − .01)e−79fw . Since hin = 0
for t > 84 (the “washout” phase), the ODE describing h becomes
h′ = −fwh,
the solution of which is
h(t) = h84e
−fw(t−84).
In summary, h(t) is given by:
h(t) =

.03
(
1− e−fwt) 0 ≤ t ≤ 5
.01 + (h5 − .01)e(fw(5−t)) 5 < t ≤ 84
h84e
(fw(84−t)) 84 < t.
Appendix E. Parameter values used in the bifurcation analysis. The fol-
lowing parameter values were used when generating the Figure 5.
Parameters used in the bifurcation diagram, as well as in the lower two panels:
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bB bN bT bTH dB
68 3.98 2.6 10.4 7.6× 10−3
dBN dBT dN dNB dT
1.0× 10−4 2.6× 10−2 1.59× 10−2 1.0× 10−4 5× 10−3
dTB dTH k r s
1.0× 10−3 1.0× 10−2 6.0× 10−1 1.76× 10−2 1000
Equilibrium values used in the center panel ( in cells/ µ L) :
Beq Neq Teq THeq
Stable Equilibrium 97.4 155.3 26.7 1040.8
Unstable Equilibrium 172.2 120.2 15.1 1040.9
Initial values used in the Right panels for the non-equilibrium simulations:
N(0) = 120.2 cells/µL, T (0) = 15.1 cells/µL, TH(0) = 1040.9 cells/µL
